Terazosin

When ATH:
C02CA05

Characteristic.

The white crystalline powder, without smell, soluble in water.

Pharmacological action.
Vasodilating, antidizuricescoe, gipolipidemicescoe.

Application.

Arterial hypertension, benign prostatic hyperplasia.

Contraindications.

Hypersensitivity, hypotension, pregnancy, lactation, childhood.

Restrictions apply.

IBS and other heart disease, kidney and / or liver failure, cerebrovascular accident, Hypertensive retinopathy of the III or IV degree, diabetes mellitus type 1.

Side effects.

Weakness, fatiguability, drowsiness, anxiety, headache, dizziness, paraesthesia, decreased libido, blurred vision, noise in ears, "Phenomenon of the first dose" (a sharp drop in blood pressure, up to orthostatic collapse, After the first trick, more often in combination therapy with diuretics or beta-blockers), gipotenziya, tachycardia, Arrhythmia, peripheral edema, cough, bronchitis, xerostomia, pharyngitis, nausea, vomiting, arthralgia, myalgia, decrease in hematocrit and hemoglobin levels, leukopenia, hypoalbuminemia, hypoproteinemia, flu-like symptoms, allergic reactions.

Cooperation.

Enhances the hypotensive activity of diuretics, adrenoblokatorov, calcium antagonists, myotropic drugs and drugs, inhibiting the renin-angiotensin-aldosterone system.

Antacids and adsorbents reduce absorption. Adrenergic agonists reduce effectiveness.

Overdose.

Symptoms: tachycardia, gipotenziya, Orthostatic hypotension.

Treatment: Transfer the patient to a horizontal position, with the head of the bed down, in / in a liquid, hypertensive drugs. Hemodialysis nyeeffyektivyen. No specific antidote.

Dosing and Administration.

Inside. By 1 mg once before bed; the dose is gradually increased to 10–20 mg (no more) 1 once a day.

Precautions.

After the first reception or in the initial period of treatment, the “first dose” may occur. To prevent orthostatic collapse, the initial dose should not exceed 1 mg and should be administered before bedtime (in the supine position). Reducing body fluid volume and limiting salt intake increases the risk of postural hypotension. It must be remembered, that similar phenomena can occur when treatment is resumed after a break of several days. In such cases, treatment should be resumed with a dose 1 mg.

Fainting occurs in 1% cases. The development of fainting can be caused by a rapid increase in dosage after the “first dose effect” occurs., as well as the prescription of doxazosin in combination with diuretics and/or other antihypertensive drugs.

Before starting treatment for BPH, it is necessary to exclude the presence of a malignant neoplasm.. In patients with BPH, blood pressure levels should be monitored at the beginning of treatment and when changing the dose of the drug during treatment.. It is advisable to evaluate the effectiveness of doxazosin for BPH after 4–6 weeks of treatment with maintenance doses..

At the beginning of treatment and when increasing the dose of the drug, patients are not recommended to engage in potentially hazardous activities, require increased attention and psychomotor speed reactions (incl. driving vehicles). Further, during treatment, These restrictions are set individually.

Cooperation